Numinus Wellness (NUMI) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
23 Nov, 2025Opening remarks and agenda
Meeting called to order with confirmation of quorum and virtual participation procedures outlined.
Voting conducted via Lumi Connect, with prior proxies and live votes accepted.
Board and executive committee updates
Number of directors set at four, with nominees Payton Nyquvest, Larry Timlick, Michael Tan, and Donna Wilson elected for the next term.
Majority voting policy and TSX requirements for director elections emphasized.
Shareholder proposals
Motions passed for appointment of Davidson and Company as auditors and approval for the board to set remuneration.
Omnibus Equity Incentive Plan reapproved, including unallocated entitlements.
Share consolidation at a maximum 40:1 ratio approved, with timing and ratio at board discretion.
Voluntary delisting from TSX approved, to be enacted at board's discretion in line with relisting strategy.
Latest events from Numinus Wellness
- Q1 2025 saw 68% revenue growth, higher margins, and sharply reduced losses.NUMI
Q1 2025 - Revenue surged 83.8% year-over-year, but net loss widened and cash reserves remain low.NUMI
Q2 2025 - Revenue up 16.4% in Q4 2024, with improved margins and strategic U.S. asset sale.NUMI
Q4 2024 - Revenue up 81.6% and gross margin turned positive as cost controls drive improved results.NUMI
Q3 2025 - AI-driven expansion and practitioner training fuel growth in psychedelic mental health services.NUMI
Investor Presentation - Integrated clinical, research, and training model drives growth in the expanding mental health market.NUMI
Investor Presentation - Expanding U.S. clinics, research, and training drive growth in the evolving mental health market.NUMI
Investor Presentation - Expanding U.S. operations, clinical trial growth, and licensing drive future profitability.NUMI
Maxim Group’s 2024 Healthcare Virtual Summit - Cost cuts and MedBright AI deal drive U.S. shift and scalable, tech-enabled growth.NUMI
Q3 2024